BridgeBio Pharma (BBIO) revenue breakdown
By product, Net product revenue is the largest at 72% of fiscal 2025 revenue, growing 357% a year over 3 years.
Revenue by product
Fiscal years, as BridgeBio Pharma reports them in its 10-K filings; fiscal 2025 total $502M.
| Products | 2021 | 2022 | 2024 | 2025 | Share |
|---|---|---|---|---|---|
| Net product revenue | $4M | $2M | $3M | $362M | 72% |
| License and services revenue | $66M | $76M | $219M | $128M | 26% |
| Royalty revenue | — | — | $169,000 | $11M | 2% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BBIO.
Open BBIO in InvestinglyQuestions
Where does BridgeBio Pharma make its money?
In fiscal 2025, by product: Net product revenue $362M, License and services revenue $128M, Royalty revenue $11M.
From BridgeBio Pharma's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.